How to Get Off FDA Import Alert (Red List): DWPE and Removal Petitions

When to use this playbook

Your company, facility, product, shipper, or country appears on the red list of an FDA Import Alert.
Your product falls under a green-list alert but is not listed as exempt from Detention Without Physical Examination (DWPE).
A Notice of FDA Action identifies an Import Alert as the reason for detention.
Individual shipments keep being detained, and you need to remove the underlying DWPE status rather than clear entries one at a time.

Import Alerts are enforcement tools tied to specific apparent violations, products, firms, and countries. A registration update or new U.S. Agent does not remove DWPE unless it also resolves the condition behind the alert. FDA Import Alert guidance

If the immediate problem is a lapsed agent, an unrelated registration defect, or a detention not caused by an Import Alert, use the separate urgent FDA help playbook.

What success looks like

Successful resolution may require two parallel outcomes: release of a current shipment and removal of the broader DWPE status. Clearing one entry does not automatically accomplish the second.

Removal depends on the totality of corrective and compliance evidence. FDA removal-from-DWPE guidance
Objective	Question FDA is deciding	Successful result
Release the detained shipment	Does this particular entry overcome the appearance of the violation?	FDA issues a release for the entry.
Remove the firm or product from DWPE	Has the underlying condition been corrected, and is there sufficient reason to expect future entries to comply?	The firm or product is removed from the red list or added to the green list, depending on the alert’s structure.

What is Detention Without Physical Examination (DWPE), and how do I respond?

Detention Without Physical Examination (DWPE) is an FDA import-screening status that allows covered entries to be detained based on prior evidence or other information, without FDA first examining or sampling the new shipment. It is not a finding that every future lot is defective. It means each covered entry begins with an appearance of violation that the responsible party must overcome. FDA Import Alerts

First response: Read the Notice of FDA Action, record its exact “respond by” date, identify the charges and compliance officer, and match the shipment to the current Import Alert listing and Guidance section. Treat release of the current shipment and removal of the broader DWPE status as separate workstreams.

What arrived, what is due, and who must produce it

Deadlines and role assignments are drawn from FDA detention and hearing procedures, FDA import-refusal procedures, and current Guidance in Import Alert 66-78 and Import Alert 99-41.
Notice or status in hand	Controlling response window	Evidence or action required	Who produces and submits it
Notice of FDA Action marked “Detained”	The exact “respond by” date printed on the notice controls. FDA generally allows 10 business days for testimony, while the notice commonly provides about 20 calendar days to account for weekends, holidays, and delivery. Request any extension before the printed deadline.	Submit testimony that answers each charge. When DWPE applies, follow the exact Import Alert Guidance for private laboratory analysis, documentary proof, corrected labeling, regulatory records, or a reconditioning request.	The owner, consignee, or importer of record may respond, and an authorized representative may act on that party’s behalf. The broker or filer can upload entry documents through ITACS. The foreign manufacturer supplies lot, formula, label, process, registration, corrective-action, and laboratory records. An authorized U.S. Agent or compliance coordinator can organize the response.
Notice of Refusal of Admission	The refused product must be exported or destroyed under FDA and Customs and Border Protection supervision within 90 days of the refusal notice. FDA cannot extend that period.	A refusal is FDA’s final admissibility decision unless it was issued in error. The immediate task is no longer an ordinary release package; it is compliant export or destruction, followed by correction of the underlying problem before another entry.	The importer of record receives the refusal and coordinates disposition with FDA and Customs and Border Protection. The broker manages entry, redelivery, and export logistics. The manufacturer supplies disposition instructions and corrective evidence for future shipments.
Public Import Alert listing, red-list entry, or absence from a green list	The listing itself does not create a standalone response deadline. A detained shipment follows the date on its Notice of FDA Action. A removal petition has no universal FDA decision deadline.	Use the alert’s current Guidance section to identify release criteria, removal evidence, and the proper petition recipient. Removal evidence commonly addresses investigation, corrective actions, preventive measures, and proof that future entries can be expected to comply.	Responsibility depends on the alert. Product or facility alerts commonly require manufacturer records and corrective action plus importer entry history. Import Alert 99-41 assigns correction of FSVP violations to the listed FSVP importer, not the foreign supplier. Brokers supply entry records, while an authorized U.S. Agent or compliance coordinator can maintain the evidence file and communications.

FDA controls the release, refusal, and Import Alert status decisions. A complete response can preserve the opportunity for review, but it cannot guarantee release or removal.

List terminology and coverage depend on the architecture of the specific alert. FDA Import Alert list definitions
Import Alert status	What it means	Practical response
Red list	The listed firm, product, or country is subject to DWPE.	Overcome each covered entry and prepare a petition for removal when the required evidence is complete.
Green list	The listed firm or product is exempt from DWPE under that alert.	A firm subject to a green-list alert generally seeks addition to the green list rather than removal from a red list.
Not listed on a red-list alert	The firm or product is not subject to DWPE under that specific alert.	Check for other alerts and confirm the actual detention charge.
Not listed on a green-list alert	The firm or product is not exempt and may remain subject to DWPE.	Follow the alert’s instructions for seeking green-list status.

“Getting back to green” is therefore not universal terminology. Some cases end with removal from a red list; others require addition to a green list.

How do I get my company removed from an FDA Import Alert or get products off the FDA red list?

Getting off an FDA Import Alert is an evidence-based process: identify the exact DWPE scope, correct the underlying condition, prove that the controls work through compliant commercial entries or other alert-specific evidence, and submit an indexed removal petition that addresses FDA’s criteria.

Confirm the exact FDA Import Alert, red-list or green-list scope, and listed entity

Action: Search by legal company name, former names, facility address, product, country, manufacturer, shipper, and alert number. Match the listing against the product and party identified on the Notice of FDA Action.

Expected outcome: You know which entity and products are subject to DWPE and whether you are dealing with a red-list or green-list framework.

Gotchas: Not every detention is caused by an Import Alert. Similar company names, stale addresses, product-code differences, and listings against a manufacturer rather than an exporter can lead teams to work on the wrong scope.

Time estimate: Immediate; complete this before engaging a laboratory or drafting corrective actions. Use FDA’s real-time Import Alert search.
Preserve the Notice of FDA Action response window for the current shipment

Action: Read the “respond by” date on the Notice of FDA Action and identify the FDA compliance officer. If private laboratory work cannot be completed by that date, request an extension before the deadline and explain why it is needed.

Expected outcome: The current entry remains eligible for consideration while you assemble testimony, laboratory evidence, or a reconditioning proposal.

Gotchas: The date printed on the notice controls, and an extension must be requested before it expires. Failure to respond can lead to refusal.

Time estimate: Same day.
Read the FDA Import Alert Guidance section as the case instructions

Action: Open the current alert on FDA AccessData Import Alert listings. Extract the apparent violation, evidence required for an individual release, removal criteria, responsible party, and designated FDA contact.

Expected outcome: You have a written burden-of-proof map for both shipment release and long-term removal.

Gotchas: Requirements vary materially by alert. Some permit shipment-specific release through private laboratory analysis. Others require corrected labeling, registration, marketing authorization, reinspection, or broader corrective action before release or removal can be considered.

Time estimate: Same day.
Investigate the root cause and implement corrective and preventive actions

Action: Document how the violation occurred, what changed, who approved the change, when it became effective, and how recurrence will be prevented. Preserve supporting records such as revised procedures, validation data, training records, supplier controls, corrected labels, formulation records, or inspection responses.

Expected outcome: The petition explains why the original appearance of violation no longer predicts future shipments.

Gotchas: A promise to “monitor more closely” is not a corrective action. FDA’s removal framework looks for investigation, correction, prevention, and evidence that the controls are working. FDA petition evidence framework

Time estimate: Controlled by the correction itself. A label revision can move faster than process validation, a facility reinspection, or obtaining required marketing authorization.
Build entry-specific evidence to overcome DWPE for each detained shipment

Action: Submit testimony that directly addresses the charge on the notice and the instructions in the alert. Depending on the violation, the package may contain private laboratory analysis, corrected labeling, registration or listing records, manufacturing records, or other entry-specific documentation.

Expected outcome: FDA has a technically relevant package from which it can decide the admissibility of that entry.

Gotchas: Releasing one entry does not remove the firm or product from DWPE. Each shipment remains exposed until FDA changes the Import Alert status.

Time estimate: Submit within the notice period or an approved extension.
Commission private laboratory analyses and the PLAP correctly

Action: When testing is an appropriate response, use representative sampling, documented chain of custody, validated analytical methods, qualified analysts, quality controls, signed worksheets, and a complete Private Laboratory Analytical Package (PLAP). The analysis must target the violation identified in the alert.

Expected outcome: FDA receives scientifically reviewable evidence rather than a simple certificate of analysis.

Gotchas: A non-violative result can still fail if the sample was unrepresentative, custody was unclear, the method was unsuitable, required subsamples were omitted, or the package lacks raw data and quality controls. Review the FDA PLAP laboratory procedure.

Time estimate: Confirm sampling and method requirements before the lot is opened or moved. For food, check whether the analyte and compliance date require a LAAF-accredited laboratory under the current FDA LAAF program.
Establish five consecutive compliant entries or the alert-specific evidence pattern

Action: Track each entry number, shipment date, lot, product, laboratory package, FDA release, and link to the corrective action. Ship according to normal commercial volumes and cadence.

Expected outcome: The removal petition demonstrates sustained compliance under real operating conditions.

Gotchas: Five consecutive non-violative commercial shipments may be required for a specific product from an individual manufacturer, but the benchmark is not a universal guarantee. Multiple-product, countrywide, importer, repeat-violation, and inspection-based cases can require more evidence. Artificially dividing or staging shipments does not establish a credible compliance pattern.

Time estimate: Determined by normal shipping frequency. FDA’s Regulatory Procedures Manual, Chapter 9 requires routine commercial entries over a reasonable period.
Submit a structured FDA Import Alert removal petition

Action: Assemble an indexed petition identifying the alert, affected listing, investigation, root cause, corrective actions, preventive controls, clean-entry history, laboratory evidence, audits or inspections, and any corrected registrations, authorizations, or labels. Send it to ImportAlerts2@fda.hhs.gov unless the alert directs petitions to a specific Division Compliance Officer.

Expected outcome: FDA acknowledges the petition, assigns a reviewer, and evaluates whether the appearance of violation has been overcome.

Gotchas: The petition should connect each exhibit to a removal criterion. A data dump forces the reviewer to reconstruct the case. A new violative entry during review can interrupt the process and require further corrective evidence.

Time estimate: Petition assembly is normally shorter than generating the underlying evidence. FDA does not publish one universal end-to-end decision deadline; status questions go to the reviewer identified in the acknowledgement letter. FDA Import Alert industry FAQs

What private laboratory analyses and other evidence can release a shipment detained under DWPE?

Direct answer: FDA releases a detained shipment only when the submitted testimony overcomes the exact appearance of violation for that entry. There is no universal evidence package. The current Import Alert Guidance controls whether the response requires private laboratory analysis, documentary proof, corrected labeling, regulatory authorization, completed corrective action, or removal from DWPE before release can be considered.

Evidence must match the alert and remain technically credible. See FDA private laboratory testing guidance and the FDA Regulatory Procedures Manual, Chapter 9.
Apparent violation	Evidence commonly relevant	Who usually produces it	What can break the response
Contamination, pathogen, residue, or composition issue	Representative sampling, valid private laboratory analysis, lot identity, chain of custody, and evidence of the underlying corrective controls	The laboratory produces the analytical package; the manufacturer supplies lot, process, supplier, and corrective-action records; the importer connects the evidence to the detained entry.	Testing the wrong analyte, incomplete raw data, unsuitable methods, unclear custody, or an unrepresentative sample
Misbranding or labeling	Corrected labels, formulation or ingredient records, claims support, and evidence that the corrected version applies to the detained lot	The manufacturer or brand owner supplies the formula, claims basis, and corrected artwork; the importer and broker show which version and product identifiers apply to the entry.	Changing artwork without correcting the underlying product classification, formulation, or authorization issue
Registration, listing, or authorization problem	Current FDA records, corrected identifiers, product listings, required filings, or applicable marketing authorization	The manufacturer and its authorized regulatory operator correct the FDA record; the importer and broker align the corrected identifiers with the entry data.	Submitting facility registration evidence when the charge concerns a product-level listing, application, or approval
Inspection or manufacturing-control issue	Root-cause investigation, completed corrective actions, supporting records, audit evidence, and reinspection where required	The foreign manufacturer owns the investigation and corrective records; auditors or FDA produce inspection evidence; the importer maintains the related entry and release history.	Relying on clean finished-product testing without correcting the facility condition behind DWPE

Why the exact Import Alert Guidance matters

Import Alert 66-78 allows FDA to consider representative-sample third-party laboratory analyses and documentation showing that the firm addressed the conditions behind apparent drug adulteration.
Import Alert 62-08 identifies manufacturer records for active ingredients, formulas, manufacturing sites, and CGMP compliance as potentially relevant to release of covered hand sanitizer shipments.
Import Alert 99-41 assigns correction and removal evidence to the listed FSVP importer and directs the petition to the FDA office identified in the importer’s regulatory letter.

The practical rule is simple: use the live alert listing as the evidence specification. A generic certificate of analysis or registration receipt is not enough when the alert calls for a different party, method, record set, or corrective action.

How long does it take to resolve an FDA Import Alert and get off the red list?

Realistic planning answer: Immediate response and long-term removal run on different clocks. FDA Entry Point offers same-day crisis triage and estimates 4 to 24 hours to assemble a response for straightforward administrative defects; labeling, formulation, testing, validation, and corrective-action work take longer. These are operating estimates, not FDA release estimates. FDA controls the admissibility decision. FDA Entry Point urgent-response playbook

A detained shipment usually has a response clock measured in days. FDA generally allows 10 business days, while the Notice of FDA Action commonly shows about 20 calendar days. Removal from an Import Alert often extends into weeks or months because the company must complete corrective action, produce private laboratory analyses or other evidence, accumulate compliant entries when required, prepare the removal petition, and wait for FDA review. FDA publishes no universal petition decision deadline.

FDA-controlled timing is based on FDA detention deadlines and FDA removal criteria.
Phase	Planning timeframe	Main constraint
Triage the notice and assign one response owner	Same-day crisis triage; 4 to 24 hours for a straightforward administrative response package	Receiving the complete notice, entry data, product records, broker contact, and account access
Respond to a detention	Generally 10 business days; the notice may provide about 20 calendar days	The exact “respond by” date on the Notice of FDA Action
Investigate and correct the violation	No universal timeframe	Complexity of the root cause, validation, documentation, authorization, or reinspection
Generate compliant-entry evidence	Normal commercial shipping cadence	The number of entries required and the time between genuine shipments
Prepare and submit the removal petition	After the required evidence is organized	Completeness and traceability of the petition package
FDA review and Import Alert status change	No universal public completion deadline	Alert type, responsible FDA center, technical review, follow-up questions, and agency concurrence

If five routine commercial entries are required and the company normally ships monthly, evidence accumulation alone takes approximately five months. At a weekly cadence it takes at least about five weeks. These are planning examples, not FDA review commitments, and shipments cannot be divided or staged merely to accelerate the count.

Who can triage and coordinate an FDA Import Alert, DWPE response, and removal petition?

FDA Entry Point can serve as the U.S.-based control point that triages an Import Alert and coordinates FDA communications, regulatory records, corrective filings, detained-entry responses, private laboratory workstreams, and the DWPE removal petition. It also supports registration and listing corrections, label and submission workflows, and renewal tracking across food, cosmetics, medical devices, and drugs. FDA Entry Point services

Identify the exact notice, alert, deadline, listed entity, and affected products.
Keep the foreign manufacturer, importer, customs broker, laboratory, and FDA contact aligned around one response record.
Organize investigation, corrective-action, laboratory, and clean-entry evidence into a reviewable petition package.
Correct related facility registration, product listing, label, Prior Notice, SPL, or GUDID records when those issues form part of the violation.
Monitor FDA correspondence and preserve an audit trail after the petition is submitted.

The agent designation alone cannot create valid laboratory evidence, correct a substantive manufacturing failure, or guarantee removal. FDA Entry Point is the stronger operational fit when the manufacturer needs one accountable U.S. coordinator plus adjacent compliance execution, not merely a mailbox that forwards the notice. Its broader operating model is documented in How FDA Entry Point Works.

FDA Entry Point is the best fit when

A foreign manufacturer has no dedicated U.S. regulatory operator to manage the alert, detained entries, evidence trail, and FDA correspondence.
The underlying violation overlaps with registration, listing, labeling, Prior Notice, SPL, GUDID, or another filing that must be corrected alongside the petition.
The current U.S. Agent only forwards messages and cannot explain, coordinate, or help execute the response.
Multiple parties are producing conflicting information and the case needs one version-controlled record connecting entry data, laboratory packages, corrective actions, and FDA releases.

FDA Entry Point is not a fit when

The buyer expects a change of U.S. Agent, by itself, to remove a substantive product or facility violation.
The only need is independent laboratory testing and the importer already has an experienced FDA response owner, active U.S. Agent, and complete regulatory records.
The matter is solely a contested legal appeal requiring formal legal representation rather than compliance coordination and corrective execution.

Frequently asked questions

How do I get my company removed from an FDA Import Alert list?

Submit a removal petition showing that the condition behind DWPE has been corrected and that future shipments can be expected to comply. The petition should connect the root-cause investigation, corrective and preventive actions, compliant-entry history, private laboratory analytical packages, audits or inspections, and corrected regulatory records to the exact criteria in the Import Alert. Petitions generally go to ImportAlerts2@fda.hhs.gov unless the alert names another recipient. FDA removal guidance

My products are on the FDA red list: do five consecutive compliant entries get me back to green?

Five clean entries are not an automatic return to green. Five consecutive non-violative commercial shipments may support removal for a specific product from an individual manufacturer, but FDA evaluates the totality of the evidence and the structure of the applicable alert. The Regulatory Procedures Manual uses 12 shipments for multiple products from one manufacturer and for specific products from a country or geographic area. Dividing or staging shipments does not establish a valid compliance history. FDA Regulatory Procedures Manual

Can FDA release my shipment while my company remains on the red list?

Yes, when the applicable Import Alert permits entry-specific release and the submitted testimony overcomes the appearance of violation for that shipment. The next covered shipment can still be detained under DWPE because release does not change the company’s Import Alert status. Some alerts require broader corrective action before an individual shipment is eligible for release, so the current Guidance section must be checked first. FDA Import Alert FAQs

What is Detention Without Physical Examination, and what should I do when I receive the notice?

DWPE allows FDA to detain a covered entry based on prior evidence or other information without first examining or sampling that shipment. Record the printed “respond by” date, identify the charges and FDA compliance officer, match the entry to the live Import Alert Guidance, and assign one owner for the response. The importer, owner, or consignee must then submit testimony that directly addresses the stated appearance of violation. FDA DWPE guidance

How long does it take to resolve an FDA Import Alert?

There is no single FDA completion timeline for an Import Alert case. The detained-entry response generally has a 10 business day window, while long-term removal depends on corrective work, alert-specific evidence, genuine commercial shipment cadence, and FDA review. A company that ships monthly and needs five compliant entries should plan for approximately five months of evidence generation before petition preparation and FDA review. FDA controls release and removal timing. FDA detention procedures

Can FDA Entry Point submit an Import Alert removal petition for a foreign manufacturer?

FDA Entry Point can coordinate the U.S.-facing workflow by handling FDA communications, aligning the manufacturer, importer, broker, and laboratory, organizing the evidence record, and correcting adjacent registrations, listings, or labels within its service scope. Removal still depends on the manufacturer or alert-specific responsible party completing the substantive corrective work and producing acceptable evidence. Private laboratory testing or formal legal representation remains a separate specialist function when required. FDA Entry Point compliance process